277 related articles for article (PubMed ID: 35971164)
21. Inhibition of Cyclin-Dependent Kinase 5: A Strategy to Improve Sorafenib Response in Hepatocellular Carcinoma Therapy.
Ardelt MA; Fröhlich T; Martini E; Müller M; Kanitz V; Atzberger C; Cantonati P; Meßner M; Posselt L; Lehr T; Wojtyniak JG; Ulrich M; Arnold GJ; König L; Parazzoli D; Zahler S; Rothenfußer S; Mayr D; Gerbes A; Scita G; Vollmar AM; Pachmayr J
Hepatology; 2019 Jan; 69(1):376-393. PubMed ID: 30033593
[TBL] [Abstract][Full Text] [Related]
22. Blocking CDK1/PDK1/β-Catenin signaling by CDK1 inhibitor RO3306 increased the efficacy of sorafenib treatment by targeting cancer stem cells in a preclinical model of hepatocellular carcinoma.
Wu CX; Wang XQ; Chok SH; Man K; Tsang SHY; Chan ACY; Ma KW; Xia W; Cheung TT
Theranostics; 2018; 8(14):3737-3750. PubMed ID: 30083256
[No Abstract] [Full Text] [Related]
23. Synergistic antitumor activity of sorafenib and artesunate in hepatocellular carcinoma cells.
Yao X; Zhao CR; Yin H; Wang K; Gao JJ
Acta Pharmacol Sin; 2020 Dec; 41(12):1609-1620. PubMed ID: 32300243
[TBL] [Abstract][Full Text] [Related]
24. Down-regulation of phospho-Akt is a major molecular determinant of bortezomib-induced apoptosis in hepatocellular carcinoma cells.
Chen KF; Yeh PY; Yeh KH; Lu YS; Huang SY; Cheng AL
Cancer Res; 2008 Aug; 68(16):6698-707. PubMed ID: 18701494
[TBL] [Abstract][Full Text] [Related]
25. Synergistic effects of α-Mangostin and sorafenib in hepatocellular carcinoma: New insights into α-mangostin cytotoxicity.
Wang TT; Hong YF; Chen ZH; Wu DH; Li Y; Wu XY; Huang HQ; Zhang Q; Jia CC
Biochem Biophys Res Commun; 2021 Jun; 558():14-21. PubMed ID: 33894673
[TBL] [Abstract][Full Text] [Related]
26. TNF-α is a potential therapeutic target to overcome sorafenib resistance in hepatocellular carcinoma.
Tan W; Luo X; Li W; Zhong J; Cao J; Zhu S; Chen X; Zhou R; Shang C; Chen Y
EBioMedicine; 2019 Feb; 40():446-456. PubMed ID: 30594557
[TBL] [Abstract][Full Text] [Related]
27. The kynurenine derivative 3-HAA sensitizes hepatocellular carcinoma to sorafenib by upregulating phosphatases.
Gan G; Shi Z; Shangguan C; Zhang J; Yuan Y; Chen L; Liu W; Li B; Meng S; Xiong W; Mi J
Theranostics; 2021; 11(12):6006-6018. PubMed ID: 33897895
[No Abstract] [Full Text] [Related]
28. Sorafenib enhances proteasome inhibitor-mediated cytotoxicity via inhibition of unfolded protein response and keratin phosphorylation.
Honma Y; Harada M
Exp Cell Res; 2013 Aug; 319(14):2166-78. PubMed ID: 23727131
[TBL] [Abstract][Full Text] [Related]
29. Pre-Clinical Evaluation of the Proteasome Inhibitor Ixazomib against Bortezomib-Resistant Leukemia Cells and Primary Acute Leukemia Cells.
Roeten MSF; van Meerloo J; Kwidama ZJ; Ter Huizen G; Segerink WH; Zweegman S; Kaspers GJL; Jansen G; Cloos J
Cells; 2021 Mar; 10(3):. PubMed ID: 33802801
[TBL] [Abstract][Full Text] [Related]
30. MEK inhibition by cobimetinib suppresses hepatocellular carcinoma and angiogenesis in vitro and in vivo.
Tong X; Wang Q; Wu D; Bao L; Yin T; Chen H
Biochem Biophys Res Commun; 2020 Feb; 523(1):147-152. PubMed ID: 31836141
[TBL] [Abstract][Full Text] [Related]
31. Novel cell line models to study mechanisms and overcoming strategies of proteasome inhibitor resistance in multiple myeloma.
Brünnert D; Kraus M; Stühmer T; Kirner S; Heiden R; Goyal P; Driessen C; Bargou RC; Chatterjee M
Biochim Biophys Acta Mol Basis Dis; 2019 Jun; 1865(6):1666-1676. PubMed ID: 30954557
[TBL] [Abstract][Full Text] [Related]
32. Establishment of a hepatocellular carcinoma patient-derived xenograft platform and its application in biomarker identification.
Hu B; Li H; Guo W; Sun YF; Zhang X; Tang WG; Yang LX; Xu Y; Tang XY; Ding GH; Qiu SJ; Zhou J; Li YX; Fan J; Yang XR
Int J Cancer; 2020 Mar; 146(6):1606-1617. PubMed ID: 31310010
[TBL] [Abstract][Full Text] [Related]
33. LY3214996 relieves acquired resistance to sorafenib in hepatocellular carcinoma cells.
Ma Y; Xu R; Liu X; Zhang Y; Song L; Cai S; Zhou S; Xie Y; Li A; Cao W; Tang X
Int J Med Sci; 2021; 18(6):1456-1464. PubMed ID: 33628103
[No Abstract] [Full Text] [Related]
34. Inflammatory microenvironment of fibrotic liver promotes hepatocellular carcinoma growth, metastasis and sorafenib resistance through STAT3 activation.
Jiang Y; Chen P; Hu K; Dai G; Li J; Zheng D; Yuan H; He L; Xie P; Tu M; Peng S; Qu C; Lin W; Chung RT; Hong J
J Cell Mol Med; 2021 Feb; 25(3):1568-1582. PubMed ID: 33410581
[TBL] [Abstract][Full Text] [Related]
35. Small molecule R1498 as a well-tolerated and orally active kinase inhibitor for hepatocellular carcinoma and gastric cancer treatment via targeting angiogenesis and mitosis pathways.
Zhang C; Wu X; Zhang M; Zhu L; Zhao R; Xu D; Lin Z; Liang C; Chen T; Chen L; Ren Y; Zhang J; Qin N; Zhang X
PLoS One; 2013; 8(6):e65264. PubMed ID: 23755206
[TBL] [Abstract][Full Text] [Related]
36. Sulfarotene, a synthetic retinoid, overcomes stemness and sorafenib resistance of hepatocellular carcinoma via suppressing SOS2-RAS pathway.
Qi F; Qin W; Zhang Y; Luo Y; Niu B; An Q; Yang B; Shi K; Yu Z; Chen J; Cao X; Xia J
J Exp Clin Cancer Res; 2021 Sep; 40(1):280. PubMed ID: 34479623
[TBL] [Abstract][Full Text] [Related]
37. The ubiquitin-proteasome system and its potential application in hepatocellular carcinoma therapy.
Chen YJ; Wu H; Shen XZ
Cancer Lett; 2016 Sep; 379(2):245-52. PubMed ID: 26193663
[TBL] [Abstract][Full Text] [Related]
38. Proteasome inhibitor interacts synergistically with autophagy inhibitor to suppress proliferation and induce apoptosis in hepatocellular carcinoma.
Hui B; Shi YH; Ding ZB; Zhou J; Gu CY; Peng YF; Yang H; Liu WR; Shi GM; Fan J
Cancer; 2012 Nov; 118(22):5560-71. PubMed ID: 22517429
[TBL] [Abstract][Full Text] [Related]
39. Strong enhancement by IGF1-R antagonists of hepatocellular carcinoma cell migration inhibition by Sorafenib and/or vitamin K1.
D'Alessandro R; Refolo MG; Lippolis C; Carella N; Messa C; Cavallini A; Carr BI
Cell Oncol (Dordr); 2018 Jun; 41(3):283-296. PubMed ID: 29470830
[TBL] [Abstract][Full Text] [Related]
40. A sorafenib derivative and novel SHP-1 agonist, SC-59, acts synergistically with radiotherapy in hepatocellular carcinoma cells through inhibition of STAT3.
Huang CY; Tai WT; Hsieh CY; Hsu WM; Lai YJ; Chen LJ; Shiau CW; Chen KF
Cancer Lett; 2014 Jul; 349(2):136-43. PubMed ID: 24735751
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]